Retatrutide Research Guide: Receptor Profile and Study Context
Retatrutide, also identified in the literature as LY3437943, is an engineered peptide studied for agonist activity at three class B G-protein-coupled receptors: GLP-1R, GIPR, and GCGR. Understanding that three-receptor profile requires more than repeating the phrase “triple agonist.” The assay, receptor system, molecular identity, controls, and evidence layer all determine what a result can support.
- Literature identifier: LY3437943.
- Primary receptor profile: GLP-1R, GIPR, and glucagon receptor (GCGR) agonism.
- Molecular feature: an acylated peptide whose receptor interactions have been examined with functional assays and cryo-electron microscopy.
- Evidence layers: receptor assays, structural studies, preclinical models, and registered clinical trials answer different questions.
- Catalog distinction: a labeled research vial is not interchangeable with the investigational material used in a published trial.
What is Retatrutide?
Retatrutide is the nonproprietary name used for LY3437943, a single peptide designed to engage GLP-1R, GIPR, and GCGR. Coskun and colleagues described the compound’s discovery program using in-vitro receptor assays, animal models, and an early clinical study. In their assay systems, LY3437943 showed balanced activity at GLP-1R and GCGR with comparatively greater activity at GIPR.
That description is an experimentally measured profile, not a universal ratio that can be assumed under every condition. Potency and efficacy values can shift with receptor expression, cell background, endpoint, incubation time, reference agonist, and analysis model. A laboratory record should therefore state the assay and comparator rather than describing receptor activity only with adjectives.
The three receptors are related, not interchangeable
| Research target | What distinguishes it | Useful experimental readouts |
|---|---|---|
| GLP-1 receptor (GLP-1R) | A class B GPCR with its own ligand-recognition and signaling profile. | Concentration-response curves, cAMP accumulation, efficacy relative to a defined reference agonist, and receptor-binding or structural data. |
| GIP receptor (GIPR) | A related but distinct class B GPCR; activity cannot be inferred from GLP-1R results. | Matched functional assays, receptor-selective controls, potency, efficacy, and pathway-specific measurements. |
| Glucagon receptor (GCGR) | The third named target in the Retatrutide profile and a separate experimental variable. | GCGR-specific functional assays, matched controls, signaling kinetics, and comparison with a defined glucagon-receptor reference. |
Why “triple agonist” does not mean three identical signals
A molecule can activate three receptors without producing the same potency, efficacy, kinetics, or downstream response at each one. Receptor density and signal amplification can also make a cell-based result look different from direct binding or structural observations. For a fair comparison, all three receptors should be tested with aligned methods and clearly identified reference ligands.
The most defensible output is not a single marketing number. It is a set of concentration-response data with the cell system, receptor construct, endpoint, curve model, replicate structure, and uncertainty reported. Where a study compares Retatrutide with Semaglutide or Tirzepatide, the test conditions must remain aligned before differences are attributed to molecular design.
Molecular design and receptor recognition
Structural work by Li and colleagues used cryo-electron microscopy to examine Retatrutide bound separately to GLP-1R, GIPR, and GCGR in G-protein complexes. The study mapped both shared and receptor-specific contacts and reported that the molecule is acylated through a linker at lysine position 17. This molecular feature is relevant to identity work because the intact sequence, the modification site, and the attached moiety all contribute to the expected analyte.
A shorthand compound name does not prove those features. Analytical identity should be tied to the expected molecular form and a method capable of distinguishing the intended material from truncations, substitutions, related peptides, or degradation products.
Four evidence layers that should remain separate
Measure a defined response in an engineered or native biological system. They address activity under those assay conditions.
Resolve molecular contacts and receptor conformations. They explain recognition but do not replace a functional assay.
Evaluate selected endpoints in cells or animals. Model, species, preparation, and comparator constrain interpretation.
Study a sponsor-controlled investigational material under a protocol. Results do not authenticate a separate commercial research vial.
What the published clinical literature can—and cannot—show
Jastreboff and colleagues reported a randomized phase 2 trial of sponsor-supplied Retatrutide, registered as NCT04881760. That publication establishes results for the specified investigational material, protocol, participants, endpoints, and study period. It is useful context for understanding why the receptor profile is being studied.
It does not establish the identity, fill amount, purity, sterility, stability, safety, or equivalence of an independently supplied catalog vial. Those attributes require product- and batch-specific evidence. ELMNTPEP listings are laboratory research materials and are not the investigational drug used in the cited trial.
Retatrutide research formats in the ELMNTPEP catalog
| Listing | Labeled catalog format | Live record |
|---|---|---|
| Retatrutide — 10mg | One research vial labeled at 10mg | View current price and stock |
| Retatrutide — 20mg | One research vial labeled at 20mg | View current price and stock |
| Retatrutide Starter Kit | Two 10mg research vials, one bacteriostatic-water vial, and ten syringes | View package contents and stock |
The stated milligram amount is a catalog label claim, not a dosing or administration recommendation. Product pages are the authoritative source for current price and availability; backorders are disabled so an orderable item must have live inventory.
Analytical questions for a Retatrutide research material
A useful documentation review begins by separating identity, chromatographic purity, quantity, and biological activity. These are different measurements and one result should not be used as a substitute for another.
Does mass-based or orthogonal evidence address the intended intact molecular form and modification?
Does the report identify the method, detector, integration basis, specification, and sample or batch?
Is quantity evaluated with an appropriate quantitative method rather than inferred from peak-area purity?
Can the vial label, product record, report identifier, and laboratory record be connected to the same material?
If activity matters, is it measured in a defined functional assay with receptor-selective controls?
Does the conclusion remain within what the method actually measured?
How Retatrutide differs from Semaglutide and Tirzepatide
At the receptor-profile level, Semaglutide is studied primarily as a GLP-1R agonist, Tirzepatide as a GIPR/GLP-1R dual agonist, and Retatrutide as a GIPR/GLP-1R/GCGR triple agonist. That target count is a useful starting distinction, but it is not a complete comparison of sequence, acylation, receptor bias, assay potency, stability, or experimental outcome.
Use the Semaglutide vs Tirzepatide vs Retatrutide research comparison for the broader receptor map, or browse all research peptide comparisons.
Documentation, storage, and experimental records
Review the testing documentation guide before interpreting an identity or purity result. Testing documentation is available. Certificates of analysis will be posted to the site as they become available.
Use the research peptide storage and handling checklist to record receipt, label condition, storage state, preparation, aliquots, and excursions. Product- and method-specific documentation should take precedence over generic assumptions.
Primary research references
- Coskun et al. (2022) described the discovery and early functional characterization of LY3437943 across GLP-1R, GIPR, and GCGR research systems.
- Li et al. (2024) reported cryo-EM structures and receptor-recognition analyses for Retatrutide bound to each of its three named receptors.
- Jastreboff et al. (2023) reported a randomized phase 2 study of the sponsor-controlled investigational material.
- ClinicalTrials.gov NCT04881760 provides the registered protocol-level record connected to that phase 2 study.
Compare labeled format, current price, live inventory, and related GLP research products.
Research use notice: This article provides educational molecular, analytical, literature, and catalog context. It does not provide medical, dosing, administration, performance, or therapeutic guidance. ELMNTPEP products are intended for laboratory research use only and are not for human or veterinary consumption.
View labeled strength, package contents, current price, and live stock on one product-family page.
